From: Psoriasis seems often underdiagnosed in patient with axial spondyloarthritis
Total included axSpA patients (n = 448) | AxSpA patients without self-reported psoriasis (n = 390) | AxSpA patients with self-reported psoriasis (n = 58) | AxSpA patients with self-reported psoriasis with verified diagnosis (n = 28) | AxSpA patients with self-reported psoriasis without verified diagnosis (n = 30) | |
---|---|---|---|---|---|
Age (years) | 52.2 ± 12.8 | 50.1 ± 12.7 | 52.2 ± 12.8 | 49.3 ± 13.0 | 55.0 ± 12.2 |
Sex (% male) | 287 (64.1) | 241 (62.3) | 44 (75.9)* | 19 (67.9) | 25 (83.3) |
HLA-B27 + | 339 (78.5) | 294 (78.6) | 43 (74.1) | 19 (73.1) | 24 (82.8) |
Smoking | 289 (67.4) | 248 (67.0) | 38 (65.5) | 18 (69.2) | 20 (66.7) |
BMI, at baseline (kg/m2) | 26.3 [23.4–29.1] | 26.1 [23.2–29.1] | 27.1 [25.3–30.1]* | 27.9 [26.2–30.1] | 26.6 [25.2–29.5] |
Duration of SpA symptomsa (years) | 21.0 [12.0–32.0] | 22.0 [12.0–32.8] | 19.0 [9.0–33.0] | 17.0 [6.0–29.0] | 24.0 [14.0–41.0] |
Age of onset SpA symptomsa (years) | 24.9 [19.5–33.1] | 24.5 [19.0–32.3] | 26.8 [21.3–37.1] | 29.5 [23.3–35.5] | 25.7 [20.0–37.9] |
Anti-TNF history | 252 (56.3) | 212 (54.8) | 37 (63.8) | 18 (64.3) | 19 (63.3) |
History of IBD | 46 (10.3) | 34 (8.8) | 11 (19.0)* | 4 (14.3) | 7 (23.3) |
History of peripheral arthritis | 161 (38.6) | 134 (37.4) | 25 (43.1) | 11 (42.3) | 14 (46.7) |
History of uveitisa | 134 (29.9) | 118 (30.5) | 17 (29.3) | 4 (14.3) | 4 (13.3) |
History of enthesitis | 89 (20.0) | 79 (20.6) | 8 (13.8) | 5 (17.9) | 10 (33.3) |
History of dactylitis | 30 (6.8) | 24 (6.2) | 6 (10.3) | 4 (14.3) | 2 (6.7) |
ASDASCRP | 2.2 ± 1.0 | 2.2 ± 1.0 | 2.0 ± 1.0 | 1.9 ± 0.9 | 2.1 ± 1.0 |
BASDAI | 3.7 ± 2.2 | 3.7 ± 2.2 | 3.7 ± 2.2 | 3.5 ± 2.2 | 3.8 ± 2.2 |
CRP | 3 [2–6] | 3 [2–6] | 2.0 [1.0–5.0]* | 2.0 [1.2–3.3] | 2.0 [1.0–6.1] |
ASQoL | 4.5 [1–9] | 4.4 [1–9] | 5.6 [1.3–9.0] | 3.8 [1.8–9.3] | 7.0 [1.8–8.6] |